TOT BIOPHARM Unveils Results of Phase III Clinical Trial of TAB008（Bevacizumab Injection）in ESMO ASIA for the First Time
TOT BIOPHARM International Company Limited 東曜藥業股份有限公司
TOT BIOPHARM Announces 2020 Interim Results
TOT BIOPHARM Announces First Patient Dosed in Phase III Clinical Trial of ADC Candidate TAA013
TOT BIOPHARM Self-Developed Biological Drug TAB008 (Pusintin®) Meets Primary Endpoint in Phase III Clinical Trial
TOT BIOPHARM International Company Limited TOT BIOPHARM Appoints Dr. Liu Jun as Chief Operating Officer
TOT BIOPHARM International Company Limited TOT BIOPHARM Announces 2019 Annual Results
Happy Mid-autumn Festival!
Science and technology for huai, yao see the future!
TOT BIOPHARM signed an exclusive licensing agreement for monoclonal antibody TAB014 with li's pharmaceutical company
Wang rongping carried out special research on the "four new highlands" in suzhou
Be in the lead! TOT BIOPHARM will release ADC drug TAA013 clinical phase I data
The first subjects in the phase I study of TOT BIOPHARM antibody-coupled drug were enrolled for administration
TAA013, an antibody coupled drug of TOT BIOPHARM has been approved clinically
Touching life - remember cancer star story reading club
TOT completed the B round financing of 102 million us dollars.